BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired ...

Fintel reports that on November 18, 2024, BTIG initiated coverage of VYNE Therapeutics (NasdaqCM:VYNE) with a Buy ...

BTIG raised the firm’s price target on Syndax (SNDX) to $43 from $35 and keeps a Buy rating on the shares. The firm cites the company having ...